Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain
Lund, Sweden and Princeton, New Jersey — 12 July 2017 — Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) today announced positive results from a Phase 2 pharmacokinetic study of weekly and monthly buprenorphine (CAM2038) depots in opioid dependent patients with moderate to severe non-cancer chronic pain. A total of 65 participants were enrolled and received one of three doses of CAM2038 after being transitioned from sublingual buprenorphine. The primary study objective was to characterize steady-state pharmacokinetic (PK) profiles after repeated dosing of CAM2038, including